Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia

18 sierpnia 2026 zaktualizowane przez: General Hospital of Ningxia Medical University
At the initiation of induction for non-intubated general anesthesia, ciprofol or propofol will be administered intravenously at a rate of 10 mL/min. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to evaluate sedation depth. This study aims to assess the effects of ciprofol and propofol on hemodynamics and respiratory function in elderly patients undergoing non-intubated general anesthesia.

Przegląd badań

Szczegółowy opis

Inclusion Criteria

  1. Patients scheduled for elective non-intubated general anesthesia
  2. Age ranging from 65 to 80 years old
  3. American Society of Anesthesiologists (ASA) physical status class I-III
  4. Written informed consent signed by the patient or legal guardian

Exclusion Criteria

  1. Confirmed allergy to propofol, ciprofol or their excipients
  2. Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
  3. Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
  4. Severe hepatic or renal insufficiency
  5. Long-term regular use of sedatives or opioids
  6. Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria

1. Patients with allergic reactions to study drugs or other severe complications during the trial

2. Severe hypoxemia requiring emergency endotracheal intubation

3. Severe hemodynamic instability occurring during induction

4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).

Observation Indicators

Baseline Demographic Data

Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.

Primary Observation Indicators

Hemodynamic parameters (Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR)) and respiratory parameters (peripheral oxygen saturation (SpO₂), respiratory rate (RR), end-tidal carbon dioxide (EtCO₂)) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.

Secondary Observation Indicators

  1. Baseline BIS value and minimum BIS value during induction
  2. Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
  3. Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.

Anesthetic Protocol

All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.

Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.

Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.

Rescue Management Protocols

  • Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
  • Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
  • Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
  • Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
  • Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

108

Faza

  • Faza 4

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Ningxia
      • Yinchuan, Ningxia, Chiny, 750000
        • Rekrutacyjny
        • Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  1. Patients scheduled for elective non-intubated general anesthesia
  2. Age ranging from 65 to 80 years old
  3. American Society of Anesthesiologists (ASA) physical status class I-III
  4. Written informed consent signed by the patient or legal guardian

Exclusion Criteria:

  1. Confirmed allergy to propofol, ciprofol or their excipients
  2. Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
  3. Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
  4. Severe hepatic or renal insufficiency
  5. Long-term regular use of sedatives or opioids
  6. Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia. The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min. The administration will cease when the MOAA/S score is ≤1. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction. The safety of the medication will be evaluated in comparison with the control group
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
Aktywny komparator: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point. Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction. This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Ramy czasowe: 5 minutes after induction of anesthesia
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients. Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia. Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions. Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation, respiratory rate , end-tidal carbon dioxid within the 5-minute induction period. A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
5 minutes after induction of anesthesia

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Brain electrical activity sedation depth (BIS)
Ramy czasowe: 5 minutes after induction of anesthesia
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
5 minutes after induction of anesthesia
incidence of induction period circulatory/respiratory adverse events
Ramy czasowe: 5 minutes after induction of anesthesia
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
5 minutes after induction of anesthesia

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 lipca 2026

Zakończenie podstawowe (Szacowany)

1 lutego 2027

Ukończenie studiów (Szacowany)

1 kwietnia 2027

Daty rejestracji na studia

Pierwszy przesłany

22 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

26 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 sierpnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

18 sierpnia 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj